Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
Jupiter Neurosciences (NASDAQ:JUNS) has appointed Jean Fallacara, a renowned entrepreneur and neuroscientist, as the third brand ambassador for their consumer longevity supplement line Nugevia™. Fallacara, recognized as one of the "Most Disruptive Entrepreneurs 2023," brings extensive experience in biohacking and biotechnology, including founding Z-Sciences, which was acquired by inTEST Corp in 2021.
Nugevia™ is built on JOTROL™, Jupiter's patented resveratrol-based micellar delivery platform with enhanced bioavailability. The product line includes three formulations: GLO, MND, and PWR, designed to support cellular resilience. This consumer initiative is part of Jupiter's dual-path strategy, targeting the longevity market projected to reach $8 trillion by 2030, while supporting their clinical development programs.
Jupiter Neurosciences (NASDAQ:JUNS) ha nominato Jean Fallacara, noto imprenditore e neuroscienziato, come terzo brand ambassador della linea di integratori per la longevità consumer Nugevia™. Fallacara, incluso tra i "Most Disruptive Entrepreneurs 2023", vanta una vasta esperienza in biohacking e biotecnologie, tra cui la fondazione di Z-Sciences, acquisita da inTEST Corp nel 2021.
Nugevia™ si basa su JOTROL™, la piattaforma brevettata di somministrazione micellare a base di resveratrolo di Jupiter, con una biodisponibilità migliorata. La linea comprende tre formulazioni: GLO, MND e PWR, progettate per sostenere la resilienza cellulare. Questa iniziativa consumer fa parte della strategia a doppia via di Jupiter, rivolta al mercato della longevità previsto raggiungere 8 trilioni di dollari entro il 2030, supportando al contempo i loro programmi di sviluppo clinico.
Jupiter Neurosciences (NASDAQ:JUNS) ha designado a Jean Fallacara, conocido emprendedor y neurocientífico, como el tercer embajador de marca para su línea de suplementos de longevidad para consumo Nugevia™. Fallacara, reconocido entre los "Most Disruptive Entrepreneurs 2023", aporta amplia experiencia en biohacking y biotecnología, incluida la fundación de Z-Sciences, adquirida por inTEST Corp en 2021.
Nugevia™ se basa en JOTROL™, la plataforma de entrega micelar basada en resveratrol y patentada por Jupiter, con biodisponibilidad mejorada. La gama incluye tres formulaciones: GLO, MND y PWR, diseñadas para apoyar la resiliencia celular. Esta iniciativa de consumo forma parte de la estrategia de doble vía de Jupiter, dirigida al mercado de longevidad proyectado a 8 billones de dólares para 2030, mientras respalda sus programas de desarrollo clínico.
Jupiter Neurosciences (NASDAQ:JUNS)가 유명한 기업가이자 신경과학자인 Jean Fallacara를 소비자 건강 보조식품 라인 Nugevia™의 세 번째 브랜드 앰버서더로 임명했습니다. 2023년 가장 혁신적인 기업가 중 한 명으로 꼽힌 Fallacara는 생물학적 해킹(biohacking)과 생명공학 분야에서 광범위한 경험을 보유하고 있으며, 2021년 inTEST Corp에 인수된 Z-Sciences의 설립자이기도 합니다.
Nugevia™는 JOTROL™에 기반한 재공급 플랫폼으로, 레스베라트롤 기반의 미셀랄 전달 시스템을 특허를 통해 보유하고 있어 생체 이용률이 향상되었습니다. 이 라인은 GLO, MND, PWR의 세 가지 포뮬레이션으로 구성되어 세포 회복력을 돕도록 설계되었습니다. 이 소비자 이니셔티브는 Jupiter의 이중 경로 전략의 일부로, 2030년까지 8조 달러에 이를 것으로 예측되는 장수 시장을 겨냥하며 임상 개발 프로그램도 지원합니다.
Jupiter Neurosciences (NASDAQ:JUNS) a nommé Jean Fallacara, entrepreneur renommé et neuroscientifique, comme troisième ambassadeur de marque pour leur ligne de compléments de longévité grand public Nugevia™. Fallacara, reconnu parmi les « Most Disruptive Entrepreneurs 2023 », apporte une vaste expérience en biohacking et biotechnologies, y compris la fondation de Z-Sciences, acquise par inTEST Corp en 2021.
Nugevia™ repose sur JOTROL™, la plateforme brevetée de délivrance micellaire à base de resvératrol de Jupiter, avec une biodisponibilité améliorée. La gamme comprend trois formulations : GLO, MND et PWR, conçues pour soutenir la résilience cellulaire. Cette initiative grand public s’inscrit dans la stratégie à double voie de Jupiter, visant le marché de la longévité, estimé à 8 trillions de dollars d’ici 2030, tout en soutenant leurs programmes de développement clinique.
Jupiter Neurosciences (NASDAQ:JUNS) hat Jean Fallacara, einen renommierten Unternehmer und Neurowissenschaftler, zum dritten Markenbotschafter ihrer Consumer-Longevity-Produktlinie Nugevia™ ernannt. Fallacara, der zu den „Most Disruptive Entrepreneurs 2023“ gezählt wird, bringt umfassende Erfahrungen in Biohacking und Biotechnologie mit, unter anderem als Gründer von Z-Sciences, das 2021 von inTEST Corp übernommen wurde.
Nugevia™ basiert auf JOTROL™, Jupiter's patentierter micellar delivery-Plattform auf Resveratrol-Basis mit verbesserter Bioverfügbarkeit. Die Produktreihe umfasst drei Formulierungen: GLO, MND und PWR, die entwickelt wurden, um die zelluläre Widerstandsfähigkeit zu unterstützen. Diese Verbraucherinitiative ist Teil der Dual-Path-Strategie von Jupiter, die den Longevity-Markt, der voraussichtlich bis 2030 8 Billionen Dollar erreichen wird, anvisiert und gleichzeitig ihre klinischen Entwicklungsprogramme unterstützt.
Jupiter Neurosciences (NASDAQ:JUNS) قد عيّنت جان فلاقارا، رائد أعمال وعالم أعصاب مشهور، كـ السفير الإعلامي الثالث لخط مكملات طول العمر للمستهلكين Nugevia™. فلاقارا، وهو واحد من بين «أكثر رواد الأعمال تشويشاً 2023»، يجلب خبرة واسعة في البيوهacking والتكنولوجيا الحيوية، بما في ذلك تأسيس Z-Sciences التي استحوذت عليها شركة inTEST Corp في 2021.
يستند Nugevia™ إلى JOTROL™، منصة التوصيل الميكسلية المعتمدة على الريسفيراترول بمستوى امتصاص حيوي محسن. تتضمن السلسلة ثلاث تركيبات: GLO وMND وPWR، مصممة لدعم متانة الخلايا. هذه المبادرة الاستهلاكية جزء من استراتيجية Jupiter المزدوجة المسار، الموجهة إلى سوق طول العمر المتوقع أن يصل إلى 8 تريليون دولار بحلول 2030، مع دعم برامج التطوير السريري لديها.
Jupiter Neurosciences (NASDAQ:JUNS) 已任命著名企业家和神经科学家 Jean Fallacara 为其面向消费者的长寿补充品系列 Nugevia™ 的第三位品牌大使。Fallacara 入选“2023年最具颠覆性的企业家”之一，在生物黑客和生物技术领域拥有丰富经验，包括创立 Z-Sciences，2021 年被 inTEST Corp 收购。
Nugevia™ 基于 JOTROL™，这是 Jupiter 的专利性抗坏血酸基微胶囊递送平台，具有更高的生物利用度。该产品线包括三个配方：GLO、MND 和 PWR，旨在支持细胞的弹性。这一面向消费者的倡议是 Jupiter 双路线策略的一部分，目标锁定预计到 2030 年将达到 8 万亿美元的<长寿市场，同时支持其临床开发计划。
- Strategic entry into the $8 trillion longevity market by 2030
- Partnership with high-profile brand ambassador enhances market visibility
- Leveraging patented JOTROL technology for consumer products
- Potential new revenue stream to support clinical development
- Early stage of consumer product launch with unproven market acceptance
- Competitive pressure in crowded supplement market
Partnership strengthens Nugevia™ launch bringing clinical and
scientific integrity to the fast-growing longevity space
Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Jean Fallacara, visionary entrepreneur, neuroscientist, and internationally recognized biohacker, has joined the Company as the third official brand ambassador for Nugevia™, Jupiter Neurosciences’ new consumer longevity supplement line.
Visionary entrepreneur and biohacker Jean Fallacara named Nugevia™ brand ambassador
Fallacara, known globally for pioneering advances in biohacking, biotechnology, and human performance, has earned recognition as one of the “Most Disruptive Entrepreneurs 2023” and a “Top Biohacking Influencer 2022.” With a career spanning more than three decades, he has founded and led multiple ventures, including Z-Sciences, which was acquired by NYSE American-listed inTEST Corp in 2021. He is also the founder of Lifespanning Media, a platform dedicated to extending and enriching human lifespan through science, art, health, and technology.
“Jean embodies the principles at the heart of Nugevia™: longevity, resilience, and human optimization supported by real science,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “His relentless pursuit of innovation, coupled with his ability to merge science and lifestyle, makes him a powerful advocate for our mission to help people look, feel, and perform their best at every stage of life.”
Fallacara commented, “Resveratrol has always been an overlooked cornerstone of longevity, as essential as NAD or NMN. Nugevia™ takes this breakthrough molecule and finally unlocks its full potential, merging real science with wellness innovation to deliver energy, focus, and cellular health for anyone striving to live and perform at their best. Nugevia™ is not just another supplement, it represents the convergence of clinical research, biotechnology, and wellness innovation. I believe in making human longevity accessible to everyone, and Nugevia’s products are built on the kind of real science that makes this possible. Whether you are an athlete, entrepreneur, or simply someone striving to optimize your quality of life, Nugevia™ provides the foundation for thriving in mind, body, and soul.”
Nugevia™ is built on JOTROL™, Jupiter’s patented resveratrol-based micellar delivery platform that has demonstrated significantly enhanced bioavailability and underpins the Company’s clinical-stage CNS therapies. The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL™ system.
The Nugevia™ brand reflects Jupiter’s dual-path strategy, advancing clinically validated therapeutics while tapping into the rapidly growing longevity market, projected to reach
A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, including indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
IR@jupiterneurosciences.com
JUNS@redchip.com
FAQ
What is Jupiter Neurosciences' (JUNS) Nugevia supplement line?
Who is Jean Fallacara and why did JUNS choose him as brand ambassador?
How does Nugevia fit into Jupiter Neurosciences' business strategy?
What is the market potential for Jupiter Neurosciences' Nugevia products?
What technology does Jupiter Neurosciences use in Nugevia supplements?
